"It does not make any sense. I find it astonishing that after all the controversy about ezetimibe the FDA would approve another combination product with a drug that has been on the market for a decade and has not been shown to improve cardiovascular outcomes."
The FDA has rejected Merck's Liptruzet twice before, in 2009 and 2012, because the company neglected to provide necessary data.
Merck Wins FDA Nod for New Zetia-Lipitor Combo, Despite Lack of Outcomes Benefit
Liptruzet Approved By FDA To Cut Cholesterol, Despite Criticism By Cardiologists
FDA Approves Atorvastatin/Ezetimibe Combo Tablet